Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We're pledging for parity for this year's International Women's Day, joining millions around the world in celebrating the achievements of women.

Worldwide, progress towards gender parity has slowed, with the World Economic Forum predicting the gender gap wouldn't close entirely until 2133 - that's 117 years... and 9 months!

This year's International Women's Day is all about committing to accelerate gender parity and taking concrete steps to help achieve it more quickly.

IWD 2016 - Epi Group

At NDORMS, we're joining individuals around the world "pledging to move from talk to purposeful action so we can collectively help women advance equal to their numbers and realise the limitless potential they offer economies the world over". 

Join our staff and students as they pledge to accelerate gender parity; we'll be sharing their pledges in images throughout the day.

IWD 2016 - Claudia and Jenny

NDORMS is committed to advancing equality and excellence in employment and education practices and has received an Athena SWAN Silver Award in recognition of its commitment.

IWD 2016 - Sam and Wulf and Jonathan

Our Athena SWAN application encouraged self-reflection, gave us the opportunity to celebrate current successes, and provided a framework for introducing organisational and cultural changes that truly provide the open, supportive and family-friendly research environment we aim to have. 

IWD 2016 - Nikki and Jim

The Athena SWAN Self Assessment Team continually looks at opportunities to improve current processes and procedures regarding equality and diversity within NDORMS and aims to deliver different measures and actions to make NDORMS a truly welcoming and supportive environment for all staff and students.

 

See Athena SWAN at NDORMS here.

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

New PI Marie Pust aims to bring microbiome research closer to patients

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.